-transparent.png){kind=logo}
Previous investigators have suggested that the biological activity of plasma prekallikrein is defective in cystic fibrosis. In contrast, no such difference was demonstrable between normal and cystic fibrosis plasma. Esterolytic activity for the synthetic substrate p-toluene sulfonyl-arginine methyl ester (TAMe) evolved normally in cystic fibrosis plasma treated with chloroform and ellagic acid, a measure of generation of plasma kallikrein. Additionally, plasma prekallikrein (Fletcher factor) and high molecular weight kininogen (Fitzgerald factor), a substrate of plasma kallikrein, were normal. Thus, the concept that cystic fibrosis is associated with abnormalities in the plasma kallikrein-kinin system could not be supported.
G H Goldsmith, and
R C Stern, and
H Saito, and
O D Ratnoff
November 1976,
Thrombosis research,
G H Goldsmith, and
R C Stern, and
H Saito, and
O D Ratnoff
August 2005,
Current drug targets,
G H Goldsmith, and
R C Stern, and
H Saito, and
O D Ratnoff
February 1979,
Proceedings of the National Academy of Sciences of the United States of America,
G H Goldsmith, and
R C Stern, and
H Saito, and
O D Ratnoff
January 1980,
The American journal of pediatric hematology/oncology,
G H Goldsmith, and
R C Stern, and
H Saito, and
O D Ratnoff
January 1979,
Advances in experimental medicine and biology,
G H Goldsmith, and
R C Stern, and
H Saito, and
O D Ratnoff
March 1974,
The American review of respiratory disease,
G H Goldsmith, and
R C Stern, and
H Saito, and
O D Ratnoff
January 1987,
Seminars in thrombosis and hemostasis,
G H Goldsmith, and
R C Stern, and
H Saito, and
O D Ratnoff
July 1983,
Thrombosis research,
G H Goldsmith, and
R C Stern, and
H Saito, and
O D Ratnoff
April 1980,
The Journal of laboratory and clinical medicine,
G H Goldsmith, and
R C Stern, and
H Saito, and
O D Ratnoff
September 1974,
The American review of respiratory disease,
